Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to ...
TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the ...
TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
The Ontario Drug Benefit (ODB) Formulary is the official listing that determines which prescription medicines are covered under the public insurance system in Ontario, Canada's largest province. This ...
TARRYTOWN, N.Y., Dec. 11, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive two-year results from the Phase 3 PANORAMA trial evaluating EYLEA ® (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — The 24-month results of the PRO-CON study did ...
BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA ® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FORT LAUDERDALE, Fla. — Patients with intermediate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results